SGX Pharmaceuticals
SGX Pharmaceuticals is a San Diego-based biotechnology company, founded in 1998 and now delisted, that historically focused on discovering and developing therapeutics for oncology indications.
- Company typePrivate
- Founded1998
- HeadquartersSan Diego, United States
- Headcount101–250
- GTM typeB2B
- OfferingHardware or Manufacturing
What SGX Pharmaceuticals does
SGX Pharmaceuticals is a biotechnology company founded in 1998 and headquartered in San Diego, California, focused on discovering, developing, and commercializing therapeutics that address medical needs in oncology. The company operated as a publicly listed entity on NASDAQ under the ticker SGXP and is now delisted; its corporate domain (sgxpharma.com) has lapsed and is being resold through a third-party marketplace, indicating the original operating entity is no longer active under that name. The firm employed between 101 and 250 people, consistent with a clinical-stage development organization carrying out laboratory and translational research activities.
The company's core activity centers on oncology drug discovery and development. No specific product candidates, target programs, mechanism-of-action details, platform technologies, or pipeline disclosures are present in the available input, so the precise therapeutic focus cannot be further specified from evidence on hand. A $25,000,000 private financing was completed on November 20, 2007 with participation from Great Point Partners and OrbiMed, and Louis Bock is listed in a Director capacity. There are no documented customers, distribution channels, pricing models, partnerships, or commercial revenue figures in the input material; the only pricing reference pertains to the resale price of the lapsed domain name.
SGX Pharmaceuticals firmographics
Firmographics- Name
- SGX Pharmaceuticals
- Website
- https://sgxpharma.com
- Company type
- Private
- Founded year
- 1998
- Headcount range
- 101–250 employees
- Short description
- SGX Pharmaceuticals is a San Diego-based biotechnology company, founded in 1998 and now delisted, that historically focused on discovering and developing therapeutics for oncology indications.
- Ownership category
- akta.pro rank
SGX Pharmaceuticals industry classification
Industry- Product category
- Oncology Therapeutics
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Primary Care & General Medicine Pharmaceuticals (HLAIAAAA)
Keywords
Where SGX Pharmaceuticals is headquartered
LocationHeadquarters
- HQ city
- San Diego
- HQ country
- United States
- HQ region
- North America
Markets served
SGX Pharmaceuticals business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| One time/ perpetual license | — | Domain purchase - one-time payment |
| Other | Multi-year contract | Domain purchase - payment plan |
SGX Pharmaceuticals product offering
Product offeringCore offering
SGX Pharmaceuticals is a biotechnology company that discovers, develops and markets therapeutics addressing medical needs in oncology. The company focused on the identification and advancement of small-molecule drug candidates targeting cancer, leveraging its San Diego-based research operations to build a pipeline of oncology therapeutics.
Differentiator
Problem solved
Functional benefit
Companies that use SGX Pharmaceuticals
Customer profileIdeal customer profiles1 record
SGX Pharmaceuticals technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
SGX Pharmaceuticals partnerships and signals
Strategic signalRecent moves2 records
Expansion highlights1 record
SGX Pharmaceuticals competitors and assessment
Company assessmentDirect peers
- Ambit Biosciences: Ambit Biosciences was a San Diego-based oncology biotech developing kinase inhibitors, paralleling SGX in location, therapeutic focus, and small-molecule discovery approach. It was acquired by Daiichi Sankyo, illustrating a similar strategic-exit trajectory.
- Array BioPharma: Array BioPharma was a small-molecule oncology-focused biotech developing targeted therapies across multiple cancer indications. It operated with a similar profile of pipeline-driven oncology R&D and was ultimately acquired by a large pharmaceutical company.
- Infinity Pharmaceuticals: Infinity Pharmaceuticals is a small-molecule oncology biotech developing targeted cancer therapeutics, sharing SGX's focus on oncology drug discovery and pipeline-driven development model. Both companies operated as specialty oncology platform biotechs.
- Onyx Pharmaceuticals: Onyx Pharmaceuticals was an oncology-focused biotech developing targeted cancer therapeutics, including kinase inhibitors. Its profile and acquisition history (acquired by Amgen) parallel the strategic trajectory of SGX as a specialty oncology platform company.
- Exelixis: Exelixis is an oncology-focused biotech developing small-molecule therapeutics, including kinase inhibitors, against cancer targets. It shares SGX's therapeutic focus on oncology and small-molecule discovery, though at a much larger scale and with continued independent operations.
- Cytokinetics: Cytokinetics is a California-based biotech developing small-molecule therapeutics with oncology programs alongside other therapeutic areas. It shares the California location and small-molecule oncology-discovery orientation of SGX, though with a broader therapeutic portfolio.
- Clovis Oncology: Clovis Oncology is a small-molecule oncology biotech developing targeted cancer therapies, paralleling SGX's therapeutic focus and pipeline-driven biotech model. It operates as a specialty oncology platform company in the same addressable market.
- Plexxikon: Plexxikon was a structure-guided small-molecule drug discovery company focused on oncology, closely paralleling SGX's platform-based approach to discovering targeted cancer therapeutics. Both were specialty oncology biotechs developing kinase and other targeted inhibitors using rational drug design.
Broad incumbents
- Eli Lilly and Company: Eli Lilly is a global pharmaceutical incumbent with significant oncology operations. Public reporting indicates Lilly acquired SGX Pharmaceuticals, making Lilly both a strategic acquirer in the small-molecule oncology space and a relevant comparable as the entity that absorbed SGX's pipeline and capabilities.
Emerging players
- Astex Therapeutics: Astex Therapeutics specialized in structure-based drug design using fragment-based screening approaches, closely paralleling SGX's structure-guided drug-discovery platform. Both companies leveraged structural biology to discover novel small-molecule therapeutics.
Market position
Strengths2 records
Weaknesses4 records
Competitive moat2 records
Key risks4 records
Key highlights4 records
Customer concentration
SGX Pharmaceuticals social profiles
Digital presenceSGX Pharmaceuticals financial estimates
Financial estimateRevenue estimate
Valuation estimate
SGX Pharmaceuticals leadership team
Management profileNumber of profiles
Profiles1 record
SGX Pharmaceuticals funding detail
Funding detailFunding overview
Funding rounds1 record
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
SGX Pharmaceuticals M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about SGX Pharmaceuticals
What does SGX Pharmaceuticals do?
SGX Pharmaceuticals is a biotechnology company that discovers, develops and markets therapeutics addressing medical needs in oncology. The company focused on the identification and advancement of small-molecule drug candidates targeting cancer, leveraging its San Diego-based research operations to build a pipeline of oncology therapeutics.
Is SGX Pharmaceuticals a public or private company?
SGX Pharmaceuticals is a private company. It is classified as unknown.
When was SGX Pharmaceuticals founded?
SGX Pharmaceuticals was founded in 1998. It employs 101 to 250 people.
Where is SGX Pharmaceuticals based?
SGX Pharmaceuticals is headquartered in San Diego, United States, in the North America region.
Who are SGX Pharmaceuticals's main competitors?
Direct peers on record are Ambit Biosciences, Array BioPharma, Infinity Pharmaceuticals, Onyx Pharmaceuticals, Exelixis, Cytokinetics, Clovis Oncology and Plexxikon. Eli Lilly and Company is listed as a broad incumbent. Astex Therapeutics is listed as an emerging player.
Does SGX Pharmaceuticals have an API?
No public API is recorded for SGX Pharmaceuticals.
What industry is SGX Pharmaceuticals in?
SGX Pharmaceuticals's product category is Oncology Therapeutics. Its primary akta.pro industry code is HLAIAAAA, Primary Care & General Medicine Pharmaceuticals. Its NAICS code is 541714 and its SIC code is 2834.